Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976881 | 0.91 | GBA1 (0.46) | GBA1KDM2BHSP90AB1HCRTR1HCRTR2 | |
| SCHEMBL4980285 | 0.91 | GBA1 (0.55) | GBA1KDM2BPTPN11HSP90AB1HCRTR1 | |
| SCHEMBL4976950 | 0.90 | GBA1 (0.45) | GBA1KDM2BHSP90AB1HCRTR1HCRTR2 | |
| SCHEMBL4973606 | 0.90 | PTPN11 (0.44) | GBA1KDM2BPTPN11HSP90AB1CHRM2 | |
| SCHEMBL4979609 | 0.88 | HSP90AB1 (0.44) | GBA1KDM2BPTPN11HSP90AB1HCRTR1 | |
| SCHEMBL4976933 | 0.87 | PTPN11 (0.48) | GBA1KDM2BPTPN11HSP90AB1HCRTR1 | |
| SCHEMBL4980539 | 0.86 | HSP90AB1 (0.48) | GBA1KDM2BPTPN11HSP90AB1HCRTR1 | |
| SCHEMBL4976323 | 0.85 | ALDH1A1 (0.56) | PTPN11HSP90AB1HCRTR1HCRTR2HSP90AA1 | |
| SCHEMBL4976947 | 0.84 | MEN1 (0.53) | GBA1PTPN11HSP90AB1HCRTR1HCRTR2 | |
| SCHEMBL4980433 | 0.84 | HSP90AA1 (0.44) | KDM2BPTPN11HSP90AB1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | GBA1 3687/4885KDM2B 1937/4885PTPN11 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.